PIK3CA mutations occur in ~30% of squamous cervical cancers. No PI3Ki/AKTi approval in ce...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-PIK3CA-HOTSPOT-CERVICAL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-CERVICAL |
| Sources | SRC-CIVIC SRC-ESMO-CERVICAL-2024 SRC-NCCN-CERVICAL-2025 |
Actionability Facts
| Biomarker | BIO-PIK3CA-MUTATION |
|---|---|
| Variant | hotspot (E545K / E542K / H1047R) |
| Disease | DIS-CERVICAL |
| ESCAT tier | IIIA |
| Evidence summary | PIK3CA mutations occur in ~30% of squamous cervical cancers. No PI3Ki/AKTi approval in cervical (2026); investigational in tissue-agnostic basket trials. ICI (pembrolizumab, cemiplimab) remains the targeted-therapy backbone. |
Notes
ESCAT IIIA. Off-label/trial-only in cervical.
Used By
No reverse references found in the YAML corpus.